Epigenetics Market by Product (Kit [Antibodies, Reagents], Enzyme), Service (Single-Cell Epigenomics, Multi-omics), Method (DNA Methylation, Histone Modification), Technique (NGS, PCR, MS), Application (Oncology, Immunology, CVD) - Global Forecast to 2031
The epigenetics market is expected to reach USD 3.92 billion in 2031 from USD 2.22 billion in 2026, at a CAGR of 12.0% during the forecast period. The market is expected to grow steadily during the forecast period, driven by increasing use of epigenetic analysis in oncology research, precision medicine, drug discovery, biomarker validation, and translational studies. Technologies such as next-generation sequencing, PCR & qPCR, mass spectrometry, sonication-based chromatin preparation, and methylation arrays enable the analysis of DNA methylation, histone modifications, chromatin accessibility, non-coding RNAs, and chromatin remodeling. These tools support applications across cancer diagnostics, therapeutic target identification, disease classification, treatment response monitoring, developmental biology, immunology, neuroscience, and metabolic disease research. The growing use of liquid biopsy-based methylation biomarkers, single-cell epigenomics, multi-omics integration, and AI-enabled data interpretation is further strengthening adoption across pharmaceutical, biotechnology, academic, clinical, and CRO settings. In addition, demand for standardized kits, high-quality antibodies, sequencing reagents, enzymes, automated sample preparation solutions, and bioinformatics platforms is improving workflow reproducibility and data reliability. However, market growth continues to be challenged by high sequencing and analysis costs, complex data interpretation, variability in antibody performance, and difficulties in standardizing epigenetic workflows for broader clinical use.
“DNA methylation segment is expected to grow at the highest CAGR during the forecast period”
The DNA methylation segment is projected to grow at the highest CAGR in the epigenetics market due to its increasing use in cancer detection, biomarker discovery, disease classification, and treatment response monitoring. DNA methylation assays are widely used to study promoter methylation, gene silencing, epigenetic aging, tumor profiling, and liquid biopsy-based diagnostics. The growing adoption of bisulfite sequencing, methylation-specific PCR, methylation arrays, and NGS-based methylation profiling is strengthening demand across pharmaceutical research, clinical laboratories, and translational studies.
“Next-generation sequencing segment holds the largest share of the market”
The next-generation sequencing segment accounts for the largest share of the epigenetics market, driven by its ability to generate high-throughput, genome-wide insights into epigenetic regulation. NGS is widely used in DNA methylation profiling, ChIP-seq, ATAC-seq, chromatin accessibility studies, and single-cell epigenomics. Its strong adoption across oncology research, biomarker discovery, drug development, and precision medicine supports its leading position. The increasing need for deeper epigenomic coverage, scalable analysis, and integration with multi-omics workflows continues to strengthen demand for NGS-based epigenetics solutions.
“The US is expected to grow at the highest CAGR during the forecast period”
The US is expected to grow at the highest CAGR in the epigenetics market due to its strong presence of sequencing, molecular biology, diagnostics, and bioinformatics companies, advanced research infrastructure, and high adoption of epigenomic technologies across research and clinical settings. Rising use of epigenetics in oncology, precision medicine, drug discovery, liquid biopsy development, and biomarker validation is driving market growth. Technologies such as next-generation sequencing, PCR & qPCR, methylation arrays, ChIP-seq, ATAC-seq, and single-cell epigenomics are widely used across pharmaceutical companies, biotechnology firms, academic institutes, CROs, and clinical laboratories.
The primary interviews conducted for this report can be categorized as follows:
Research Coverage
This research report categorizes the epigenetics market by offering (products and services), product [kits & reagents {antibodies, isolation/extraction kits & reagents, ChIP-sequencing kits & reagents, bisulfite conversion kits & reagents, whole-genome amplification kits & reagents, CUT&RUN/CUT&TAG kits & reagents, 5-hmC & 5-mC analysis kits & reagents, histones, and other kits & reagents}, enzymes {DNA polymerases, DNA ligases, Tn5 transposase, conversion enzymes [TET & APOBEC], protein-modifying enzymes, and other enzymes}, and instruments & accessories], service (DNA methylation profiling services, chromatin profiling services, chromatin accessibility profiling services, single-cell epigenomics services, multi-omics services, and other services), technology (next-generation sequencing, PCR & qPCR, mass spectrometry, sonication, and other technologies), method (DNA methylation, histone modifications, and other methods), application (oncology, metabolic diseases, immunology, developmental biology, cardiovascular diseases, population screening, and other applications), products market by end user (academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinics, and contract research organizations), services market by end user (pharmaceutical & biotechnology companies, academic & research institutes, hospitals & clinics, and contract research organizations), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the epigenetics market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the epigenetics market. This report also includes a competitive analysis of emerging startups in the epigenetics industry ecosystem.
Key Benefits of Buying the Report
The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
“DNA methylation segment is expected to grow at the highest CAGR during the forecast period”
The DNA methylation segment is projected to grow at the highest CAGR in the epigenetics market due to its increasing use in cancer detection, biomarker discovery, disease classification, and treatment response monitoring. DNA methylation assays are widely used to study promoter methylation, gene silencing, epigenetic aging, tumor profiling, and liquid biopsy-based diagnostics. The growing adoption of bisulfite sequencing, methylation-specific PCR, methylation arrays, and NGS-based methylation profiling is strengthening demand across pharmaceutical research, clinical laboratories, and translational studies.
“Next-generation sequencing segment holds the largest share of the market”
The next-generation sequencing segment accounts for the largest share of the epigenetics market, driven by its ability to generate high-throughput, genome-wide insights into epigenetic regulation. NGS is widely used in DNA methylation profiling, ChIP-seq, ATAC-seq, chromatin accessibility studies, and single-cell epigenomics. Its strong adoption across oncology research, biomarker discovery, drug development, and precision medicine supports its leading position. The increasing need for deeper epigenomic coverage, scalable analysis, and integration with multi-omics workflows continues to strengthen demand for NGS-based epigenetics solutions.
“The US is expected to grow at the highest CAGR during the forecast period”
The US is expected to grow at the highest CAGR in the epigenetics market due to its strong presence of sequencing, molecular biology, diagnostics, and bioinformatics companies, advanced research infrastructure, and high adoption of epigenomic technologies across research and clinical settings. Rising use of epigenetics in oncology, precision medicine, drug discovery, liquid biopsy development, and biomarker validation is driving market growth. Technologies such as next-generation sequencing, PCR & qPCR, methylation arrays, ChIP-seq, ATAC-seq, and single-cell epigenomics are widely used across pharmaceutical companies, biotechnology firms, academic institutes, CROs, and clinical laboratories.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side – 70% and Demand Side– 30%
- By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25%
- By Region: North America – 40%, Europe – 25%, Asia Pacific – 25%, Latin America – 5%, the Middle East & Africa – 5%
Research Coverage
This research report categorizes the epigenetics market by offering (products and services), product [kits & reagents {antibodies, isolation/extraction kits & reagents, ChIP-sequencing kits & reagents, bisulfite conversion kits & reagents, whole-genome amplification kits & reagents, CUT&RUN/CUT&TAG kits & reagents, 5-hmC & 5-mC analysis kits & reagents, histones, and other kits & reagents}, enzymes {DNA polymerases, DNA ligases, Tn5 transposase, conversion enzymes [TET & APOBEC], protein-modifying enzymes, and other enzymes}, and instruments & accessories], service (DNA methylation profiling services, chromatin profiling services, chromatin accessibility profiling services, single-cell epigenomics services, multi-omics services, and other services), technology (next-generation sequencing, PCR & qPCR, mass spectrometry, sonication, and other technologies), method (DNA methylation, histone modifications, and other methods), application (oncology, metabolic diseases, immunology, developmental biology, cardiovascular diseases, population screening, and other applications), products market by end user (academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinics, and contract research organizations), services market by end user (pharmaceutical & biotechnology companies, academic & research institutes, hospitals & clinics, and contract research organizations), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the epigenetics market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the epigenetics market. This report also includes a competitive analysis of emerging startups in the epigenetics industry ecosystem.
Key Benefits of Buying the Report
The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (declining sequencing costs and time, growing emphasis on population screening programs, technological advancements in epigenetics research, rising demand for epigenetic drugs and epigenetic-based therapeutics), restraints (limited applications of epigenomic data in toxicology, data privacy concerns and security issues), opportunities (emerging applications of epigenetics, integration of multi-omics), and challenges (concerns regarding quality of antibodies, challenges associated with epigenetic editing) influencing the market growth
- Product Development/Innovation: Detailed insights into newly launched products and innovations in the epigenetics market
- Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the epigenetics market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and products & services of leading players like Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), Active Motif, Inc. (US), New England Biolabs (US), QIAGEN (Netherlands), Zymo Research Corporation (US), and Revvity (US), among others, for the epigenetics market
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN EPIGENETICS MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 EPIGENETICS MARKET OVERVIEW
3.2 NORTH AMERICA: EPIGENETICS MARKET, BY METHOD AND COUNTRY
3.3 EPIGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.4 EPIGENETICS MARKET SHARE, BY OFFERING, 2026 VS. 2031
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Declining sequencing costs and time
4.2.1.2 Growing emphasis on population-scale screening initiatives
4.2.1.3 Technological advancements in epigenetics research
4.2.1.4 Rising demand for epigenetic drugs and epigenetic-based therapeutics
4.2.2 RESTRAINTS
4.2.2.1 Limited applications of epigenomic data in toxicology
4.2.2.2 Data privacy concerns and security issues
4.2.3 OPPORTUNITIES
4.2.3.1 Emerging applications of epigenetics
4.2.3.2 Integration of multi-omics
4.2.4 CHALLENGES
4.2.4.1 Concerns regarding quality of antibodies
4.2.4.2 Challenges associated with epigenetic editing
4.3 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4 TRENDS IN GLOBAL BIOTECH & PHARMA INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.4.1 ROLE OF PLAYERS IN ECOSYSTEM
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023–2025
5.5.1.1 Average selling price trend, by instrument, 2023–2025
5.5.1.2 Average selling price trend, by kits & reagents, 2023–2025
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025
5.6 TRADE ANALYSIS
5.6.1 IMPORT SCENARIO (HS CODE 9027.50)
5.6.2 EXPORT SCENARIO (HS CODE 9027.50)
5.6.3 IMPORT SCENARIO (HS CODE 3822.00)
5.6.4 EXPORT SCENARIO (HS CODE 3822.00)
5.7 KEY CONFERENCES & EVENTS, 2026–2027
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.9 INVESTMENT & FUNDING SCENARIO
5.10 CASE STUDY ANALYSIS
5.10.1 CFDNA METHYLOME–FRAGMENTOME PROFILING STRENGTHENS MULTICANCER DETECTION
5.10.2 5-BASE NGS WORKFLOW ENABLES INTEGRATED METHYLATION AND VARIANT PROFILING
5.10.3 LONG-READ SEQUENCING SCALES NATIVE EPIGENOME ANALYSIS IN AGING RESEARCH
5.11 IMPACT OF 2025 US TARIFF ON EPIGENETICS MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON COUNTRIES/REGIONS
5.11.4.1 US
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON END-USE INDUSTRIES
5.11.5.1 Pharmaceutical and biotechnology companies
5.11.5.2 Contract research organizations
5.11.5.3 Academic and research institutes
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 INTRODUCTION
6.1.1 KEY TECHNOLOGIES
6.1.1.1 DNA methylation conversion technologies
6.1.1.2 Chromatin immunoprecipitation/ChIP
6.1.1.3 ATAC-based chromatin accessibility profiling
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Single-cell partitioning and epigenomic barcoding
6.1.2.2 AI/ML-based epigenomic interpretation
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 CRISPR-based epigenome modulation
6.1.3.2 Spatial epigenomics
6.2 TECHNOLOGY ROADMAP
6.3 PATENT ANALYSIS
6.3.1 METHODOLOGY
6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
6.3.3 LIST OF KEY PATENTS
6.4 FUTURE APPLICATIONS
6.5 IMPACT OF AI/GEN AI ON EPIGENETICS MARKET
6.5.1 TOP USE CASES AND MARKET POTENTIAL
6.5.2 BEST PRACTICES IN AI-ENABLED EPIGENETICS WORKFLOWS
6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN EPIGENETICS MARKET
6.5.4 INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.5.5 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED EPIGENETICS TECHNOLOGIES
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Asia Pacific
7.1.2.4 Rest of the World
7.2 SUSTAINABILITY INITIATIVES
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
7.4 CERTIFICATIONS, LABELING, & ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9 EPIGENETICS MARKET, BY OFFERING
9.1 INTRODUCTION
9.2 PRODUCTS
9.2.1 RISING ADOPTION OF WORKFLOW-READY EPIGENETICS PRODUCTS TO PROPEL MARKET
9.3 SERVICES
9.3.1 RISING OUTSOURCING OF COMPLEX EPIGENOMIC WORKFLOWS TO DRIVE MARKET
10 EPIGENETICS MARKET, BY PRODUCT
10.1 INTRODUCTION
10.2 KITS & REAGENTS
10.2.1 ANTIBODIES
10.2.1.1 Growing demand for recombinant antibodies for detection of epigenetic targets to propel market
10.2.2 ISOLATION/EXTRACTION KITS & REAGENTS
10.2.2.1 Rising need for high-quality, automation-ready sample preparation to propel market
10.2.3 CHIP-SEQUENCING KITS & REAGENTS
10.2.3.1 Versatile applications of chromatin immunoprecipitation pertaining to epigenetic regulatory systems to boost market
10.2.4 BISULFITE CONVERSION KITS & REAGENTS
10.2.4.1 Effective outcomes associated with bisulfite conversion to sustain growth
10.2.5 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS
10.2.5.1 Rising use of low-input and single-cell epigenomic workflows to stimulate growth
10.2.6 CUT&RUN/CUT&TAG KITS & REAGENTS
10.2.6.1 Rising adoption of low-input chromatin profiling workflows to stimulate growth
10.2.7 5-HMC & 5-MC ANALYSIS KITS & REAGENTS
10.2.7.1 Introduction of unique kits for 5-mC and 5-hmC analysis to support growth
10.2.8 HISTONES
10.2.8.1 Rising importance of chromatin-associated proteins and histones in epigenetic research to propel growth
10.2.9 OTHER KITS & REAGENTS
10.3 ENZYMES
10.3.1 DNA POLYMERASES
10.3.1.1 Rising need for uracil-tolerant, low-bias DNA amplification to facilitate growth
10.3.2 DNA LIGASES
10.3.2.1 Rising need for efficient adapter ligation in low-input epigenomic library preparation to spur growth
10.3.3 TN5 TRANSPOSASE
10.3.3.1 Rising adoption of tagmentation-based chromatin profiling to facilitate growth
10.3.4 CONVERSION ENZYMES
10.3.4.1 Rising shift toward enzymatic DNA conversion for low-damage methylome profiling to spur growth
10.3.5 PROTEIN-MODIFYING ENZYMES
10.3.5.1 Rising focus on histone post-translational modification analysis to spur growth
10.3.6 OTHER ENZYMES
10.4 INSTRUMENTS & ACCESSORIES
10.4.1 RISING ADOPTION OF HIGH-THROUGHPUT, AUTOMATED, AND LONG-READ EPIGENOMIC PLATFORMS TO EXPEDITE GROWTH
11 EPIGENETICS MARKET, BY SERVICE
11.1 INTRODUCTION
11.2 DNA METHYLATION PROFILING SERVICES
11.2.1 OUTSOURCING OF COMPLEX METHYLATION WORKFLOWS AND ONCOLOGY BIOMARKER RESEARCH TO DRIVE MARKET
11.3 CHROMATIN PROFILING SERVICES
11.3.1 RISING OUTSOURCING OF LOW-INPUT AND MULTI-OMIC CHROMATIN MAPPING WORKFLOWS TO DRIVE MARKET
11.4 CHROMATIN ACCESSIBILITY PROFILING SERVICES
11.4.1 RISING USE OF SINGLE-CELL EPIGENOMIC PROFILING IN EMBRYO AND LINEAGE-DEVELOPMENT RESEARCH TO PROPEL MARKET
11.5 SINGLE-CELL EPIGENOMICS SERVICES
11.5.1 RISING NEED FOR CELL-LEVEL REGULATORY INSIGHTS TO AID GROWTH
11.6 MULTI-OMICS SERVICES
11.6.1 RISING DEMAND FOR INTEGRATED EPIGENOMIC, GENOMIC, AND TRANSCRIPTOMIC INTERPRETATION TO SUPPORT GROWTH
11.7 OTHER SERVICES
12 EPIGENETICS MARKET, BY TECHNOLOGY
12.1 INTRODUCTION
12.2 NEXT-GENERATION SEQUENCING
12.2.1 INCREASING LAUNCHES OF NGS PLATFORMS TO DRIVE GROWTH
12.3 PCR & QPCR
12.3.1 RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO DRIVE MARKET
12.4 MASS SPECTROMETRY
12.4.1 GROWING DEMAND FOR MASS SPECTROMETRY IN COMPREHENSIVE STUDIES ON HISTONE EPIGENETICS TO BOOST MARKET
12.5 SONICATION
12.5.1 RISING USE OF SONICATION IN SCIENTIFIC AND INDUSTRIAL SETTINGS TO DRIVE MARKET
12.6 OTHER TECHNOLOGIES
13 EPIGENETICS MARKET, BY METHOD
13.1 INTRODUCTION
13.2 DNA METHYLATION
13.2.1 RISING USE OF METHYLATION-BASED BIOMARKERS IN ONCOLOGY, LIQUID BIOPSY, AND PRECISION MEDICINE TO SPUR GROWTH
13.3 HISTONE MODIFICATION
13.3.1 EXPANDING USE OF HISTONE MODIFICATION PROFILING IN CHROMATIN BIOLOGY, DRUG DISCOVERY, AND MULTI-OMICS RESEARCH TO DRIVE MARKET
13.4 OTHER METHODS
14 EPIGENETICS MARKET, BY APPLICATION
14.1 INTRODUCTION
14.2 ONCOLOGY
14.2.1 RISING USE OF EPIGENETIC BIOMARKERS AND CHROMATIN-REGULATING DRUG TARGETS TO BOOST MARKET
14.3 METABOLIC DISEASES
14.3.1 INCREASING USE OF DNA METHYLATION BIOMARKERS TO ADVANCE METABOLIC DISEASE RISK PREDICTION AND THERAPEUTIC RESEARCH
14.4 IMMUNOLOGY
14.4.1 RISING USE OF EPIGENETIC IMMUNE PROFILING TO DRIVE MARKET
14.5 DEVELOPMENTAL BIOLOGY
14.5.1 INCREASED USE OF SINGLE-CELL EPIGENOMIC PROFILING IN EMBRYO AND LINEAGE-DEVELOPMENT RESEARCH TO PROPEL MARKET
14.6 CARDIOVASCULAR DISEASES
14.6.1 RISING USE OF DNA METHYLATION BIOMARKERS FOR CARDIOVASCULAR RISK PREDICTION AND THERAPEUTIC TARGET DISCOVERY TO AID GROWTH
14.7 POPULATION SCREENING
14.7.1 INCREASING USE OF DNA METHYLATION BIOMARKERS FOR EXPOSURE-LINKED POPULATION RISK ASSESSMENT TO AID GROWTH
14.8 OTHER APPLICATIONS
15 EPIGENETIC PRODUCTS MARKET, BY END USER
15.1 INTRODUCTION
15.2 ACADEMIC & RESEARCH INSTITUTES
15.2.1 INCREASED IN-HOUSE ADOPTION OF ADVANCED EPIGENOMICS PRODUCTS ACROSS ACADEMIC DISCOVERY RESEARCH TO FAVOR GROWTH
15.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
15.3.1 RISING USE OF EPIGENETICS PRODUCTS IN DRUG DISCOVERY TO PROPEL MARKET
15.4 HOSPITALS & CLINICS
15.4.1 RISING INTEGRATION OF METHYLATION-BASED MOLECULAR PROFILING IN HOSPITAL ONCOLOGY WORKFLOWS TO PROPEL MARKET
15.5 CONTRACT RESEARCH ORGANIZATIONS
15.5.1 INCREASING DEMAND FOR STANDARDIZED AND SCALABLE EPIGENOMIC WORKFLOWS TO DRIVE MARKET
16 EPIGENETICS SERVICES MARKET, BY END USER
16.1 INTRODUCTION
16.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
16.2.1 RISING USE OF OUTSOURCED EPIGENETIC BIOMARKER AND TARGET-VALIDATION SERVICES TO ACCELERATE DRUG DEVELOPMENT DECISIONS
16.3 ACADEMIC & RESEARCH INSTITUTES
16.3.1 INCREASING VOLUME OF HIGH-THROUGHPUT EPIGENOMIC DATA TO AUGMENT GROWTH
16.4 HOSPITALS & CLINICS
16.4.1 RISING USE OF OUTSOURCED METHYLATION PROFILING AND CLASSIFIER-BASED INTERPRETATION TO AID GROWTH
17 EPIGENETICS MARKET, BY REGION
17.1 INTRODUCTION
17.2 NORTH AMERICA
17.2.1 US
17.2.1.1 Strong pharmaceutical R&D intensity and advanced genomics infrastructure to drive market
17.2.2 CANADA
17.2.2.1 Presence of advanced clinical genomics infrastructure to support market growth
17.3 EUROPE
17.3.1 GERMANY
17.3.1.1 Established life sciences supply ecosystem to drive market
17.3.2 UK
17.3.2.1 Growing emphasis on precision medicine to propel market
17.3.3 FRANCE
17.3.3.1 Strong oncology research ecosystem to support market growth
17.3.4 ITALY
17.3.4.1 High incidence of cancer to drive market
17.3.5 SPAIN
17.3.5.1 Well-established network of research centers and universities to propel market
17.3.6 REST OF EUROPE
17.4 ASIA PACIFIC
17.4.1 CHINA
17.4.1.1 Advanced methylation detection and sequencing service capacity to accelerate growth
17.4.2 JAPAN
17.4.2.1 Increasing collaborations between research & academic organizations to favor growth
17.4.3 INDIA
17.4.3.1 Expanding genomics infrastructure to drive market
17.4.4 AUSTRALIA
17.4.4.1 Strong genomics infrastructure to propel market
17.4.5 SOUTH KOREA
17.4.5.1 Methylation profiling and AI-enabled epigenomic analysis to foster growth
17.4.6 REST OF ASIA PACIFIC
17.5 LATIN AMERICA
17.5.1 BRAZIL
17.5.1.1 Rising prevalence of chronic diseases to drive market
17.5.2 MEXICO
17.5.2.1 Growing adoption of cutting-edge technologies to drive market
17.5.3 REST OF LATIN AMERICA
17.6 MIDDLE EAST
17.6.1 GCC COUNTRIES
17.6.1.1 Saudi Arabia
17.6.1.1.1 Growing healthcare expenditure to propel market
17.6.1.2 UAE
17.6.1.2.1 National genomics programs and methylation-enabled sequencing to spur growth
17.6.1.3 Rest of GCC countries
17.6.2 REST OF MIDDLE EAST
17.7 AFRICA
17.7.1 POPULATION-SPECIFIC BIOMARKER DISCOVERY AND DISEASE-FOCUSED METHYLATION RESEARCH TO AUGMENT GROWTH
18 COMPETITIVE LANDSCAPE
18.1 INTRODUCTION
18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2023–MAY 2026
18.3 REVENUE ANALYSIS
18.4 MARKET SHARE ANALYSIS, 2025
18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
18.5.1 STARS
18.5.2 EMERGING LEADERS
18.5.3 PERVASIVE PLAYERS
18.5.4 PARTICIPANTS
18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
18.5.5.1 Company footprint
18.5.5.2 Region footprint
18.5.5.3 Product footprint
18.5.5.4 Service footprint
18.5.5.5 Method footprint
18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
18.6.1 PROGRESSIVE COMPANIES
18.6.2 RESPONSIVE COMPANIES
18.6.3 DYNAMIC COMPANIES
18.6.4 STARTING BLOCKS
18.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
18.6.5.1 Detailed list of key startups/SMEs
18.6.5.2 Competitive benchmarking of key startups/SMEs
18.7 COMPANY VALUATION AND FINANCIAL METRICS
18.7.1 COMPANY VALUATION
18.7.2 FINANCIAL METRICS
18.8 BRAND COMPARISON
18.9 COMPETITIVE SCENARIO
18.9.1 PRODUCT/SERVICE LAUNCHES
18.9.2 DEALS
19 COMPANY PROFILES
19.1 KEY PLAYERS
19.1.1 THERMO FISHER SCIENTIFIC INC.
19.1.1.1 Business overview
19.1.1.2 Products/services offered
19.1.1.3 Recent developments
19.1.1.3.1 Product launches
19.1.1.3.2 Deals
19.1.1.4 MnM view
19.1.1.4.1 Key strengths
19.1.1.4.2 Strategic choices
19.1.1.4.3 Weaknesses and competitive threats
19.1.2 ILLUMINA, INC.
19.1.2.1 Business overview
19.1.2.2 Products/Services offered
19.1.2.3 Recent developments
19.1.2.3.1 Product launches
19.1.2.3.2 Deals
19.1.2.4 MnM view
19.1.2.4.1 Key strengths
19.1.2.4.2 Strategic choices
19.1.2.4.3 Weaknesses and competitive threats
19.1.3 MERCK KGAA
19.1.3.1 Business overview
19.1.3.2 Products/Services offered
19.1.3.3 MnM view
19.1.3.3.1 Key strengths
19.1.3.3.2 Strategic choices
19.1.3.3.3 Weaknesses and competitive threats
19.1.4 DANAHER CORPORATION
19.1.4.1 Business overview
19.1.4.2 Products/Services offered
19.1.4.3 Recent developments
19.1.4.3.1 Deals
19.1.4.4 MnM view
19.1.4.4.1 Key strengths
19.1.4.4.2 Strategic choices
19.1.4.4.3 Weaknesses and competitive threats
19.1.5 BIO-RAD LABORATORIES, INC.
19.1.5.1 Business overview
19.1.5.2 Products/Services offered
19.1.5.3 MnM view
19.1.5.3.1 Key strengths
19.1.5.3.2 Strategic choices
19.1.5.3.3 Weaknesses and competitive threats
19.1.6 REVVITY
19.1.6.1 Business overview
19.1.6.2 Products/Services offered
19.1.7 PACBIO
19.1.7.1 Business overview
19.1.7.2 Products/Services offered
19.1.7.3 Recent developments
19.1.7.3.1 Product launches
19.1.7.3.2 Deals
19.1.8 ACTIVE MOTIF, INC.
19.1.8.1 Business overview
19.1.8.2 Products/Services offered
19.1.8.3 Recent developments
19.1.8.3.1 Deals
19.1.9 NEW ENGLAND BIOLABS
19.1.9.1 Business overview
19.1.9.2 Products/Services offered
19.1.9.3 Recent developments
19.1.9.3.1 Product launches
19.1.9.3.2 Deals
19.1.10 QIAGEN
19.1.10.1 Business overview
19.1.10.2 Products/services offered
19.1.10.3 Recent developments
19.1.10.3.1 Product launches
19.1.11 ZYMO RESEARCH CORPORATION
19.1.11.1 Business overview
19.1.11.2 Products/Services offered
19.1.11.3 Recent developments
19.1.11.3.1 Product launches
19.1.11.3.2 Deals
19.1.12 HOLOGIC DIAGENODE
19.1.12.1 Business overview
19.1.12.2 Products/services offered
19.1.13 F. HOFFMANN-LA ROCHE LTD.
19.1.13.1 Business overview
19.1.13.2 Products/services offered
19.1.14 PROMEGA CORPORATION
19.1.14.1 Business overview
19.1.14.2 Products/services offered
19.1.15 EPIGENTEK GROUP INC.
19.1.15.1 Business overview
19.1.15.2 Products/Services offered
19.1.15.3 Recent developments
19.1.15.3.1 Product launches
19.2 OTHER PLAYERS
19.2.1 EPICYPHER
19.2.2 FIOS GENOMICS
19.2.3 GENOMESCAN
19.2.4 CREATIVE BIOGENE
19.2.5 BPS BIOSCIENCE, INC.
19.2.6 ABNOVA CORPORATION
19.2.7 CREATIVE DIAGNOSTICS
19.2.8 BIOMODAL
19.2.9 10X GENOMICS
19.2.10 NOVOGENE CO., LTD.
20 RESEARCH METHODOLOGY
20.1 RESEARCH DATA
20.1.1 SECONDARY DATA
20.1.1.1 Key data from secondary sources
20.1.2 PRIMARY DATA
20.1.2.1 Key data from primary sources
20.1.2.2 Key primary participants
20.1.2.3 Breakdown of primary interviews
20.1.2.4 Key industry insights
20.2 MARKET SIZE ESTIMATION
20.2.1 GLOBAL EPIGENETICS MARKET ESTIMATION, 2025
20.2.2 SEGMENTAL MARKET SIZE ESTIMATION
20.3 MARKET GROWTH RATE PROJECTIONS
20.4 DATA TRIANGULATION
20.5 FACTOR ANALYSIS
20.6 RESEARCH ASSUMPTIONS
20.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT
21 APPENDIX
21.1 DISCUSSION GUIDE
21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
21.3 CUSTOMIZATION OPTIONS
21.4 RELATED REPORTS
21.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN EPIGENETICS MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 EPIGENETICS MARKET OVERVIEW
3.2 NORTH AMERICA: EPIGENETICS MARKET, BY METHOD AND COUNTRY
3.3 EPIGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.4 EPIGENETICS MARKET SHARE, BY OFFERING, 2026 VS. 2031
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Declining sequencing costs and time
4.2.1.2 Growing emphasis on population-scale screening initiatives
4.2.1.3 Technological advancements in epigenetics research
4.2.1.4 Rising demand for epigenetic drugs and epigenetic-based therapeutics
4.2.2 RESTRAINTS
4.2.2.1 Limited applications of epigenomic data in toxicology
4.2.2.2 Data privacy concerns and security issues
4.2.3 OPPORTUNITIES
4.2.3.1 Emerging applications of epigenetics
4.2.3.2 Integration of multi-omics
4.2.4 CHALLENGES
4.2.4.1 Concerns regarding quality of antibodies
4.2.4.2 Challenges associated with epigenetic editing
4.3 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4 TRENDS IN GLOBAL BIOTECH & PHARMA INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.4.1 ROLE OF PLAYERS IN ECOSYSTEM
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023–2025
5.5.1.1 Average selling price trend, by instrument, 2023–2025
5.5.1.2 Average selling price trend, by kits & reagents, 2023–2025
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025
5.6 TRADE ANALYSIS
5.6.1 IMPORT SCENARIO (HS CODE 9027.50)
5.6.2 EXPORT SCENARIO (HS CODE 9027.50)
5.6.3 IMPORT SCENARIO (HS CODE 3822.00)
5.6.4 EXPORT SCENARIO (HS CODE 3822.00)
5.7 KEY CONFERENCES & EVENTS, 2026–2027
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.9 INVESTMENT & FUNDING SCENARIO
5.10 CASE STUDY ANALYSIS
5.10.1 CFDNA METHYLOME–FRAGMENTOME PROFILING STRENGTHENS MULTICANCER DETECTION
5.10.2 5-BASE NGS WORKFLOW ENABLES INTEGRATED METHYLATION AND VARIANT PROFILING
5.10.3 LONG-READ SEQUENCING SCALES NATIVE EPIGENOME ANALYSIS IN AGING RESEARCH
5.11 IMPACT OF 2025 US TARIFF ON EPIGENETICS MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON COUNTRIES/REGIONS
5.11.4.1 US
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON END-USE INDUSTRIES
5.11.5.1 Pharmaceutical and biotechnology companies
5.11.5.2 Contract research organizations
5.11.5.3 Academic and research institutes
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 INTRODUCTION
6.1.1 KEY TECHNOLOGIES
6.1.1.1 DNA methylation conversion technologies
6.1.1.2 Chromatin immunoprecipitation/ChIP
6.1.1.3 ATAC-based chromatin accessibility profiling
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Single-cell partitioning and epigenomic barcoding
6.1.2.2 AI/ML-based epigenomic interpretation
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 CRISPR-based epigenome modulation
6.1.3.2 Spatial epigenomics
6.2 TECHNOLOGY ROADMAP
6.3 PATENT ANALYSIS
6.3.1 METHODOLOGY
6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
6.3.3 LIST OF KEY PATENTS
6.4 FUTURE APPLICATIONS
6.5 IMPACT OF AI/GEN AI ON EPIGENETICS MARKET
6.5.1 TOP USE CASES AND MARKET POTENTIAL
6.5.2 BEST PRACTICES IN AI-ENABLED EPIGENETICS WORKFLOWS
6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN EPIGENETICS MARKET
6.5.4 INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.5.5 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED EPIGENETICS TECHNOLOGIES
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Asia Pacific
7.1.2.4 Rest of the World
7.2 SUSTAINABILITY INITIATIVES
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
7.4 CERTIFICATIONS, LABELING, & ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9 EPIGENETICS MARKET, BY OFFERING
9.1 INTRODUCTION
9.2 PRODUCTS
9.2.1 RISING ADOPTION OF WORKFLOW-READY EPIGENETICS PRODUCTS TO PROPEL MARKET
9.3 SERVICES
9.3.1 RISING OUTSOURCING OF COMPLEX EPIGENOMIC WORKFLOWS TO DRIVE MARKET
10 EPIGENETICS MARKET, BY PRODUCT
10.1 INTRODUCTION
10.2 KITS & REAGENTS
10.2.1 ANTIBODIES
10.2.1.1 Growing demand for recombinant antibodies for detection of epigenetic targets to propel market
10.2.2 ISOLATION/EXTRACTION KITS & REAGENTS
10.2.2.1 Rising need for high-quality, automation-ready sample preparation to propel market
10.2.3 CHIP-SEQUENCING KITS & REAGENTS
10.2.3.1 Versatile applications of chromatin immunoprecipitation pertaining to epigenetic regulatory systems to boost market
10.2.4 BISULFITE CONVERSION KITS & REAGENTS
10.2.4.1 Effective outcomes associated with bisulfite conversion to sustain growth
10.2.5 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS
10.2.5.1 Rising use of low-input and single-cell epigenomic workflows to stimulate growth
10.2.6 CUT&RUN/CUT&TAG KITS & REAGENTS
10.2.6.1 Rising adoption of low-input chromatin profiling workflows to stimulate growth
10.2.7 5-HMC & 5-MC ANALYSIS KITS & REAGENTS
10.2.7.1 Introduction of unique kits for 5-mC and 5-hmC analysis to support growth
10.2.8 HISTONES
10.2.8.1 Rising importance of chromatin-associated proteins and histones in epigenetic research to propel growth
10.2.9 OTHER KITS & REAGENTS
10.3 ENZYMES
10.3.1 DNA POLYMERASES
10.3.1.1 Rising need for uracil-tolerant, low-bias DNA amplification to facilitate growth
10.3.2 DNA LIGASES
10.3.2.1 Rising need for efficient adapter ligation in low-input epigenomic library preparation to spur growth
10.3.3 TN5 TRANSPOSASE
10.3.3.1 Rising adoption of tagmentation-based chromatin profiling to facilitate growth
10.3.4 CONVERSION ENZYMES
10.3.4.1 Rising shift toward enzymatic DNA conversion for low-damage methylome profiling to spur growth
10.3.5 PROTEIN-MODIFYING ENZYMES
10.3.5.1 Rising focus on histone post-translational modification analysis to spur growth
10.3.6 OTHER ENZYMES
10.4 INSTRUMENTS & ACCESSORIES
10.4.1 RISING ADOPTION OF HIGH-THROUGHPUT, AUTOMATED, AND LONG-READ EPIGENOMIC PLATFORMS TO EXPEDITE GROWTH
11 EPIGENETICS MARKET, BY SERVICE
11.1 INTRODUCTION
11.2 DNA METHYLATION PROFILING SERVICES
11.2.1 OUTSOURCING OF COMPLEX METHYLATION WORKFLOWS AND ONCOLOGY BIOMARKER RESEARCH TO DRIVE MARKET
11.3 CHROMATIN PROFILING SERVICES
11.3.1 RISING OUTSOURCING OF LOW-INPUT AND MULTI-OMIC CHROMATIN MAPPING WORKFLOWS TO DRIVE MARKET
11.4 CHROMATIN ACCESSIBILITY PROFILING SERVICES
11.4.1 RISING USE OF SINGLE-CELL EPIGENOMIC PROFILING IN EMBRYO AND LINEAGE-DEVELOPMENT RESEARCH TO PROPEL MARKET
11.5 SINGLE-CELL EPIGENOMICS SERVICES
11.5.1 RISING NEED FOR CELL-LEVEL REGULATORY INSIGHTS TO AID GROWTH
11.6 MULTI-OMICS SERVICES
11.6.1 RISING DEMAND FOR INTEGRATED EPIGENOMIC, GENOMIC, AND TRANSCRIPTOMIC INTERPRETATION TO SUPPORT GROWTH
11.7 OTHER SERVICES
12 EPIGENETICS MARKET, BY TECHNOLOGY
12.1 INTRODUCTION
12.2 NEXT-GENERATION SEQUENCING
12.2.1 INCREASING LAUNCHES OF NGS PLATFORMS TO DRIVE GROWTH
12.3 PCR & QPCR
12.3.1 RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO DRIVE MARKET
12.4 MASS SPECTROMETRY
12.4.1 GROWING DEMAND FOR MASS SPECTROMETRY IN COMPREHENSIVE STUDIES ON HISTONE EPIGENETICS TO BOOST MARKET
12.5 SONICATION
12.5.1 RISING USE OF SONICATION IN SCIENTIFIC AND INDUSTRIAL SETTINGS TO DRIVE MARKET
12.6 OTHER TECHNOLOGIES
13 EPIGENETICS MARKET, BY METHOD
13.1 INTRODUCTION
13.2 DNA METHYLATION
13.2.1 RISING USE OF METHYLATION-BASED BIOMARKERS IN ONCOLOGY, LIQUID BIOPSY, AND PRECISION MEDICINE TO SPUR GROWTH
13.3 HISTONE MODIFICATION
13.3.1 EXPANDING USE OF HISTONE MODIFICATION PROFILING IN CHROMATIN BIOLOGY, DRUG DISCOVERY, AND MULTI-OMICS RESEARCH TO DRIVE MARKET
13.4 OTHER METHODS
14 EPIGENETICS MARKET, BY APPLICATION
14.1 INTRODUCTION
14.2 ONCOLOGY
14.2.1 RISING USE OF EPIGENETIC BIOMARKERS AND CHROMATIN-REGULATING DRUG TARGETS TO BOOST MARKET
14.3 METABOLIC DISEASES
14.3.1 INCREASING USE OF DNA METHYLATION BIOMARKERS TO ADVANCE METABOLIC DISEASE RISK PREDICTION AND THERAPEUTIC RESEARCH
14.4 IMMUNOLOGY
14.4.1 RISING USE OF EPIGENETIC IMMUNE PROFILING TO DRIVE MARKET
14.5 DEVELOPMENTAL BIOLOGY
14.5.1 INCREASED USE OF SINGLE-CELL EPIGENOMIC PROFILING IN EMBRYO AND LINEAGE-DEVELOPMENT RESEARCH TO PROPEL MARKET
14.6 CARDIOVASCULAR DISEASES
14.6.1 RISING USE OF DNA METHYLATION BIOMARKERS FOR CARDIOVASCULAR RISK PREDICTION AND THERAPEUTIC TARGET DISCOVERY TO AID GROWTH
14.7 POPULATION SCREENING
14.7.1 INCREASING USE OF DNA METHYLATION BIOMARKERS FOR EXPOSURE-LINKED POPULATION RISK ASSESSMENT TO AID GROWTH
14.8 OTHER APPLICATIONS
15 EPIGENETIC PRODUCTS MARKET, BY END USER
15.1 INTRODUCTION
15.2 ACADEMIC & RESEARCH INSTITUTES
15.2.1 INCREASED IN-HOUSE ADOPTION OF ADVANCED EPIGENOMICS PRODUCTS ACROSS ACADEMIC DISCOVERY RESEARCH TO FAVOR GROWTH
15.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
15.3.1 RISING USE OF EPIGENETICS PRODUCTS IN DRUG DISCOVERY TO PROPEL MARKET
15.4 HOSPITALS & CLINICS
15.4.1 RISING INTEGRATION OF METHYLATION-BASED MOLECULAR PROFILING IN HOSPITAL ONCOLOGY WORKFLOWS TO PROPEL MARKET
15.5 CONTRACT RESEARCH ORGANIZATIONS
15.5.1 INCREASING DEMAND FOR STANDARDIZED AND SCALABLE EPIGENOMIC WORKFLOWS TO DRIVE MARKET
16 EPIGENETICS SERVICES MARKET, BY END USER
16.1 INTRODUCTION
16.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
16.2.1 RISING USE OF OUTSOURCED EPIGENETIC BIOMARKER AND TARGET-VALIDATION SERVICES TO ACCELERATE DRUG DEVELOPMENT DECISIONS
16.3 ACADEMIC & RESEARCH INSTITUTES
16.3.1 INCREASING VOLUME OF HIGH-THROUGHPUT EPIGENOMIC DATA TO AUGMENT GROWTH
16.4 HOSPITALS & CLINICS
16.4.1 RISING USE OF OUTSOURCED METHYLATION PROFILING AND CLASSIFIER-BASED INTERPRETATION TO AID GROWTH
17 EPIGENETICS MARKET, BY REGION
17.1 INTRODUCTION
17.2 NORTH AMERICA
17.2.1 US
17.2.1.1 Strong pharmaceutical R&D intensity and advanced genomics infrastructure to drive market
17.2.2 CANADA
17.2.2.1 Presence of advanced clinical genomics infrastructure to support market growth
17.3 EUROPE
17.3.1 GERMANY
17.3.1.1 Established life sciences supply ecosystem to drive market
17.3.2 UK
17.3.2.1 Growing emphasis on precision medicine to propel market
17.3.3 FRANCE
17.3.3.1 Strong oncology research ecosystem to support market growth
17.3.4 ITALY
17.3.4.1 High incidence of cancer to drive market
17.3.5 SPAIN
17.3.5.1 Well-established network of research centers and universities to propel market
17.3.6 REST OF EUROPE
17.4 ASIA PACIFIC
17.4.1 CHINA
17.4.1.1 Advanced methylation detection and sequencing service capacity to accelerate growth
17.4.2 JAPAN
17.4.2.1 Increasing collaborations between research & academic organizations to favor growth
17.4.3 INDIA
17.4.3.1 Expanding genomics infrastructure to drive market
17.4.4 AUSTRALIA
17.4.4.1 Strong genomics infrastructure to propel market
17.4.5 SOUTH KOREA
17.4.5.1 Methylation profiling and AI-enabled epigenomic analysis to foster growth
17.4.6 REST OF ASIA PACIFIC
17.5 LATIN AMERICA
17.5.1 BRAZIL
17.5.1.1 Rising prevalence of chronic diseases to drive market
17.5.2 MEXICO
17.5.2.1 Growing adoption of cutting-edge technologies to drive market
17.5.3 REST OF LATIN AMERICA
17.6 MIDDLE EAST
17.6.1 GCC COUNTRIES
17.6.1.1 Saudi Arabia
17.6.1.1.1 Growing healthcare expenditure to propel market
17.6.1.2 UAE
17.6.1.2.1 National genomics programs and methylation-enabled sequencing to spur growth
17.6.1.3 Rest of GCC countries
17.6.2 REST OF MIDDLE EAST
17.7 AFRICA
17.7.1 POPULATION-SPECIFIC BIOMARKER DISCOVERY AND DISEASE-FOCUSED METHYLATION RESEARCH TO AUGMENT GROWTH
18 COMPETITIVE LANDSCAPE
18.1 INTRODUCTION
18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2023–MAY 2026
18.3 REVENUE ANALYSIS
18.4 MARKET SHARE ANALYSIS, 2025
18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
18.5.1 STARS
18.5.2 EMERGING LEADERS
18.5.3 PERVASIVE PLAYERS
18.5.4 PARTICIPANTS
18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
18.5.5.1 Company footprint
18.5.5.2 Region footprint
18.5.5.3 Product footprint
18.5.5.4 Service footprint
18.5.5.5 Method footprint
18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
18.6.1 PROGRESSIVE COMPANIES
18.6.2 RESPONSIVE COMPANIES
18.6.3 DYNAMIC COMPANIES
18.6.4 STARTING BLOCKS
18.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
18.6.5.1 Detailed list of key startups/SMEs
18.6.5.2 Competitive benchmarking of key startups/SMEs
18.7 COMPANY VALUATION AND FINANCIAL METRICS
18.7.1 COMPANY VALUATION
18.7.2 FINANCIAL METRICS
18.8 BRAND COMPARISON
18.9 COMPETITIVE SCENARIO
18.9.1 PRODUCT/SERVICE LAUNCHES
18.9.2 DEALS
19 COMPANY PROFILES
19.1 KEY PLAYERS
19.1.1 THERMO FISHER SCIENTIFIC INC.
19.1.1.1 Business overview
19.1.1.2 Products/services offered
19.1.1.3 Recent developments
19.1.1.3.1 Product launches
19.1.1.3.2 Deals
19.1.1.4 MnM view
19.1.1.4.1 Key strengths
19.1.1.4.2 Strategic choices
19.1.1.4.3 Weaknesses and competitive threats
19.1.2 ILLUMINA, INC.
19.1.2.1 Business overview
19.1.2.2 Products/Services offered
19.1.2.3 Recent developments
19.1.2.3.1 Product launches
19.1.2.3.2 Deals
19.1.2.4 MnM view
19.1.2.4.1 Key strengths
19.1.2.4.2 Strategic choices
19.1.2.4.3 Weaknesses and competitive threats
19.1.3 MERCK KGAA
19.1.3.1 Business overview
19.1.3.2 Products/Services offered
19.1.3.3 MnM view
19.1.3.3.1 Key strengths
19.1.3.3.2 Strategic choices
19.1.3.3.3 Weaknesses and competitive threats
19.1.4 DANAHER CORPORATION
19.1.4.1 Business overview
19.1.4.2 Products/Services offered
19.1.4.3 Recent developments
19.1.4.3.1 Deals
19.1.4.4 MnM view
19.1.4.4.1 Key strengths
19.1.4.4.2 Strategic choices
19.1.4.4.3 Weaknesses and competitive threats
19.1.5 BIO-RAD LABORATORIES, INC.
19.1.5.1 Business overview
19.1.5.2 Products/Services offered
19.1.5.3 MnM view
19.1.5.3.1 Key strengths
19.1.5.3.2 Strategic choices
19.1.5.3.3 Weaknesses and competitive threats
19.1.6 REVVITY
19.1.6.1 Business overview
19.1.6.2 Products/Services offered
19.1.7 PACBIO
19.1.7.1 Business overview
19.1.7.2 Products/Services offered
19.1.7.3 Recent developments
19.1.7.3.1 Product launches
19.1.7.3.2 Deals
19.1.8 ACTIVE MOTIF, INC.
19.1.8.1 Business overview
19.1.8.2 Products/Services offered
19.1.8.3 Recent developments
19.1.8.3.1 Deals
19.1.9 NEW ENGLAND BIOLABS
19.1.9.1 Business overview
19.1.9.2 Products/Services offered
19.1.9.3 Recent developments
19.1.9.3.1 Product launches
19.1.9.3.2 Deals
19.1.10 QIAGEN
19.1.10.1 Business overview
19.1.10.2 Products/services offered
19.1.10.3 Recent developments
19.1.10.3.1 Product launches
19.1.11 ZYMO RESEARCH CORPORATION
19.1.11.1 Business overview
19.1.11.2 Products/Services offered
19.1.11.3 Recent developments
19.1.11.3.1 Product launches
19.1.11.3.2 Deals
19.1.12 HOLOGIC DIAGENODE
19.1.12.1 Business overview
19.1.12.2 Products/services offered
19.1.13 F. HOFFMANN-LA ROCHE LTD.
19.1.13.1 Business overview
19.1.13.2 Products/services offered
19.1.14 PROMEGA CORPORATION
19.1.14.1 Business overview
19.1.14.2 Products/services offered
19.1.15 EPIGENTEK GROUP INC.
19.1.15.1 Business overview
19.1.15.2 Products/Services offered
19.1.15.3 Recent developments
19.1.15.3.1 Product launches
19.2 OTHER PLAYERS
19.2.1 EPICYPHER
19.2.2 FIOS GENOMICS
19.2.3 GENOMESCAN
19.2.4 CREATIVE BIOGENE
19.2.5 BPS BIOSCIENCE, INC.
19.2.6 ABNOVA CORPORATION
19.2.7 CREATIVE DIAGNOSTICS
19.2.8 BIOMODAL
19.2.9 10X GENOMICS
19.2.10 NOVOGENE CO., LTD.
20 RESEARCH METHODOLOGY
20.1 RESEARCH DATA
20.1.1 SECONDARY DATA
20.1.1.1 Key data from secondary sources
20.1.2 PRIMARY DATA
20.1.2.1 Key data from primary sources
20.1.2.2 Key primary participants
20.1.2.3 Breakdown of primary interviews
20.1.2.4 Key industry insights
20.2 MARKET SIZE ESTIMATION
20.2.1 GLOBAL EPIGENETICS MARKET ESTIMATION, 2025
20.2.2 SEGMENTAL MARKET SIZE ESTIMATION
20.3 MARKET GROWTH RATE PROJECTIONS
20.4 DATA TRIANGULATION
20.5 FACTOR ANALYSIS
20.6 RESEARCH ASSUMPTIONS
20.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT
21 APPENDIX
21.1 DISCUSSION GUIDE
21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
21.3 CUSTOMIZATION OPTIONS
21.4 RELATED REPORTS
21.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 EPIGENETICS MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 EPIGENETICS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 3 EPIGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 4 EPIGENETICS MARKET: ROLE OF PLAYERS IN ECOSYSTEM
TABLE 5 AVERAGE SELLING PRICE TREND OF EPIGENETIC INSTRUMENTS, 2023–2025
TABLE 6 AVERAGE SELLING PRICE TREND OF EPIGENETIC KITS & REAGENTS, 2023–2025 (USD)
TABLE 7 AVERAGE SELLING PRICE TREND OF EPIGENETIC INSTRUMENTS, BY REGION, 2023–2025 (USD)
TABLE 8 AVERAGE SELLING PRICE TREND OF EPIGENETIC KITS & REAGENTS, BY REGION, 2023–2025 (USD)
TABLE 9 IMPORT DATA FOR HS CODE 9027.50-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 10 EXPORT DATA FOR HS CODE 9027.50-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 11 IMPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 12 EXPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 13 EPIGENETICS MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026–JUNE 2027
TABLE 14 RECIPROCAL TARIFF RATES ADJUSTED BY US
TABLE 15 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES
TABLE 16 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2015–2025
TABLE 17 LIST OF KEY PATENTS IN EPIGENETICS MARKET, 2023–2025
TABLE 18 CASE STUDIES OF AI IMPLEMENTATION IN EPIGENETICS MARKET
TABLE 19 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED EPIGENETICS TECHNOLOGIES
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
TABLE 27 KEY BUYING CRITERIA, BY END USER
TABLE 28 EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 29 EPIGENETIC PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 30 NORTH AMERICA: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31 EUROPE: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 32 ASIA PACIFIC: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33 LATIN AMERICA: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34 MIDDLE EAST: EPIGENETIC PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 35 GCC COUNTRIES: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36 EPIGENETIC SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 37 NORTH AMERICA: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 EUROPE: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39 ASIA PACIFIC: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40 LATIN AMERICA: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41 MIDDLE EAST: EPIGENETIC SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 42 GCC COUNTRIES: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43 EPIGENETICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 44 EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 45 EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 46 NORTH AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48 ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 MIDDLE EAST: EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 51 GCC COUNTRIES: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52 EPIGENETICS MARKET FOR ANTIBODIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 53 NORTH AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 EUROPE: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55 ASIA PACIFIC: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56 LATIN AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 MIDDLE EAST: EPIGENETICS MARKET FOR ANTIBODIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 58 GCC COUNTRIES: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 60 NORTH AMERICA: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61 EUROPE: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 ASIA PACIFIC: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 LATIN AMERICA: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64 MIDDLE EAST: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 65 GCC COUNTRIES: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66 EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 67 NORTH AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 EUROPE: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 69 ASIA PACIFIC: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70 LATIN AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71 MIDDLE EAST: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 72 GCC COUNTRIES: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 74 NORTH AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 EUROPE: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76 ASIA PACIFIC: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 LATIN AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78 MIDDLE EAST: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 79 GCC COUNTRIES: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 81 NORTH AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 EUROPE: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 ASIA PACIFIC: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84 LATIN AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85 MIDDLE EAST: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 86 GCC COUNTRIES: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87 EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 88 NORTH AMERICA: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 EUROPE: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90 ASIA PACIFIC: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91 LATIN AMERICA: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 MIDDLE EAST: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 93 GCC COUNTRIES: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94 EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 95 NORTH AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96 EUROPE: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97 ASIA PACIFIC: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 LATIN AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99 MIDDLE EAST: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 100 GCC COUNTRIES: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101 EPIGENETICS MARKET FOR HISTONES, BY REGION, 2024–2031 (USD MILLION)
TABLE 102 NORTH AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103 EUROPE: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105 LATIN AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106 MIDDLE EAST: EPIGENETICS MARKET FOR HISTONES, BY REGION, 2024–2031 (USD MILLION)
TABLE 107 GCC COUNTRIES: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108 EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 109 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110 EUROPE: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 114 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115 EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 116 EPIGENETICS MARKET FOR ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 117 NORTH AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120 LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121 MIDDLE EAST: EPIGENETICS MARKET FOR ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 122 GCC COUNTRIES: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 EPIGENETICS MARKET FOR DNA POLYMERASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 124 NORTH AMERICA: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 EUROPE: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 126 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 127 LATIN AMERICA: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 128 MIDDLE EAST: EPIGENETICS MARKET FOR DNA POLYMERASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 129 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 EPIGENETICS MARKET FOR DNA LIGASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 131 NORTH AMERICA: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 EUROPE: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 133 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134 LATIN AMERICA: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 MIDDLE EAST: EPIGENETICS MARKET FOR DNA LIGASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 136 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY REGION, 2024–2031 (USD MILLION)
TABLE 138 NORTH AMERICA: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 139 EUROPE: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140 ASIA PACIFIC: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141 LATIN AMERICA: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142 MIDDLE EAST: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY REGION, 2024–2031 (USD MILLION)
TABLE 143 GCC COUNTRIES: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144 EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 145 NORTH AMERICA: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146 EUROPE: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147 ASIA PACIFIC: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 LATIN AMERICA: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 149 MIDDLE EAST: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 150 GCC COUNTRIES: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 152 NORTH AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 EUROPE: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 154 ASIA PACIFIC: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155 LATIN AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156 MIDDLE EAST: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 157 GCC COUNTRIES: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158 EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 159 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160 EUROPE: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 163 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 164 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 166 NORTH AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167 EUROPE: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168 ASIA PACIFIC: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 LATIN AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 MIDDLE EAST: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 171 GCC COUNTRIES: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 EPIGENETICS MARKET, BY SERVICE, 2024–2031 (USD MILLION)
TABLE 173 EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 174 NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 LATIN AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 178 MIDDLE EAST: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 179 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 180 EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 181 NORTH AMERICA: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 EUROPE: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183 ASIA PACIFIC: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 LATIN AMERICA: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 185 MIDDLE EAST: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 186 GCC COUNTRIES: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187 EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 188 NORTH AMERICA: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 EUROPE: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190 ASIA PACIFIC: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 191 LATIN AMERICA: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 192 MIDDLE EAST: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 193 GCC COUNTRIES: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 195 NORTH AMERICA: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196 EUROPE: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 197 ASIA PACIFIC: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198 LATIN AMERICA: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199 MIDDLE EAST: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 200 GCC COUNTRIES: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 202 NORTH AMERICA: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203 EUROPE: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204 ASIA PACIFIC: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205 LATIN AMERICA: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 MIDDLE EAST: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 207 GCC COUNTRIES: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 208 EPIGENETICS MARKET FOR OTHER SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 209 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210 EUROPE: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 214 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 215 EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 216 EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024–2031 (USD MILLION)
TABLE 217 NORTH AMERICA: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218 EUROPE: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219 ASIA PACIFIC: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220 LATIN AMERICA: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 221 MIDDLE EAST: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024–2031 (USD MILLION)
TABLE 222 GCC COUNTRIES: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 223 EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2024–2031 (USD MILLION)
TABLE 224 NORTH AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225 EUROPE: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226 ASIA PACIFIC: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 227 LATIN AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228 MIDDLE EAST: EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2024–2031 (USD MILLION)
TABLE 229 GCC COUNTRIES: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230 EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 231 NORTH AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232 EUROPE: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 233 ASIA PACIFIC: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 234 LATIN AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 235 MIDDLE EAST: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 236 GCC COUNTRIES: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 237 EPIGENETICS MARKET FOR SONICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 238 NORTH AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 239 EUROPE: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240 ASIA PACIFIC: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 241 LATIN AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 242 MIDDLE EAST: EPIGENETICS MARKET FOR SONICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 243 GCC COUNTRIES: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 244 EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 245 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246 EUROPE: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 248 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 250 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 251 EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 252 EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 253 NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254 EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 256 LATIN AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 257 MIDDLE EAST: EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 258 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 259 COMMON HISTONE MODIFICATIONS AND RESPECTIVE LOCATIONS
TABLE 260 EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 261 NORTH AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 262 EUROPE: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263 ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 264 LATIN AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 265 MIDDLE EAST: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 266 GCC COUNTRIES: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 267 EPIGENETICS MARKET FOR OTHER METHODS, BY REGION, 2024–2031 (USD MILLION)
TABLE 268 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 269 EUROPE: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 1 EPIGENETICS MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 EPIGENETICS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 3 EPIGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 4 EPIGENETICS MARKET: ROLE OF PLAYERS IN ECOSYSTEM
TABLE 5 AVERAGE SELLING PRICE TREND OF EPIGENETIC INSTRUMENTS, 2023–2025
TABLE 6 AVERAGE SELLING PRICE TREND OF EPIGENETIC KITS & REAGENTS, 2023–2025 (USD)
TABLE 7 AVERAGE SELLING PRICE TREND OF EPIGENETIC INSTRUMENTS, BY REGION, 2023–2025 (USD)
TABLE 8 AVERAGE SELLING PRICE TREND OF EPIGENETIC KITS & REAGENTS, BY REGION, 2023–2025 (USD)
TABLE 9 IMPORT DATA FOR HS CODE 9027.50-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 10 EXPORT DATA FOR HS CODE 9027.50-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 11 IMPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 12 EXPORT DATA FOR HS CODE 3822.00-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD THOUSAND)
TABLE 13 EPIGENETICS MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026–JUNE 2027
TABLE 14 RECIPROCAL TARIFF RATES ADJUSTED BY US
TABLE 15 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES
TABLE 16 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2015–2025
TABLE 17 LIST OF KEY PATENTS IN EPIGENETICS MARKET, 2023–2025
TABLE 18 CASE STUDIES OF AI IMPLEMENTATION IN EPIGENETICS MARKET
TABLE 19 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED EPIGENETICS TECHNOLOGIES
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
TABLE 27 KEY BUYING CRITERIA, BY END USER
TABLE 28 EPIGENETICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
TABLE 29 EPIGENETIC PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 30 NORTH AMERICA: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31 EUROPE: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 32 ASIA PACIFIC: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33 LATIN AMERICA: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34 MIDDLE EAST: EPIGENETIC PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 35 GCC COUNTRIES: EPIGENETIC PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36 EPIGENETIC SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 37 NORTH AMERICA: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38 EUROPE: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39 ASIA PACIFIC: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40 LATIN AMERICA: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41 MIDDLE EAST: EPIGENETIC SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 42 GCC COUNTRIES: EPIGENETIC SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43 EPIGENETICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 44 EPIGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 45 EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 46 NORTH AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 EUROPE: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48 ASIA PACIFIC: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 LATIN AMERICA: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 MIDDLE EAST: EPIGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 51 GCC COUNTRIES: EPIGENETICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52 EPIGENETICS MARKET FOR ANTIBODIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 53 NORTH AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 EUROPE: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55 ASIA PACIFIC: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56 LATIN AMERICA: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 MIDDLE EAST: EPIGENETICS MARKET FOR ANTIBODIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 58 GCC COUNTRIES: EPIGENETICS MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59 EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 60 NORTH AMERICA: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61 EUROPE: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 ASIA PACIFIC: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 LATIN AMERICA: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64 MIDDLE EAST: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 65 GCC COUNTRIES: EPIGENETICS MARKET FOR ISOLATION/EXTRACTION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66 EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 67 NORTH AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 EUROPE: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 69 ASIA PACIFIC: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70 LATIN AMERICA: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71 MIDDLE EAST: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 72 GCC COUNTRIES: EPIGENETICS MARKET FOR CHIP-SEQUENCING KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 74 NORTH AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 EUROPE: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76 ASIA PACIFIC: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77 LATIN AMERICA: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78 MIDDLE EAST: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 79 GCC COUNTRIES: EPIGENETICS MARKET FOR BISULFITE CONVERSION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 81 NORTH AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 EUROPE: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 ASIA PACIFIC: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 84 LATIN AMERICA: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85 MIDDLE EAST: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 86 GCC COUNTRIES: EPIGENETICS MARKET FOR WHOLE-GENOME AMPLIFICATION KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87 EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 88 NORTH AMERICA: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 EUROPE: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90 ASIA PACIFIC: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91 LATIN AMERICA: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 MIDDLE EAST: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 93 GCC COUNTRIES: EPIGENETICS MARKET FOR CUT&RUN/CUT&TAG KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94 EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 95 NORTH AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 96 EUROPE: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97 ASIA PACIFIC: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 LATIN AMERICA: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99 MIDDLE EAST: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 100 GCC COUNTRIES: EPIGENETICS MARKET FOR 5-HMC & 5-MC ANALYSIS KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101 EPIGENETICS MARKET FOR HISTONES, BY REGION, 2024–2031 (USD MILLION)
TABLE 102 NORTH AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103 EUROPE: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105 LATIN AMERICA: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106 MIDDLE EAST: EPIGENETICS MARKET FOR HISTONES, BY REGION, 2024–2031 (USD MILLION)
TABLE 107 GCC COUNTRIES: EPIGENETICS MARKET FOR HISTONES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108 EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 109 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110 EUROPE: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 114 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER KITS & REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115 EPIGENETICS MARKET FOR ENZYMES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 116 EPIGENETICS MARKET FOR ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 117 NORTH AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 EUROPE: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 ASIA PACIFIC: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 120 LATIN AMERICA: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121 MIDDLE EAST: EPIGENETICS MARKET FOR ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 122 GCC COUNTRIES: EPIGENETICS MARKET FOR ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 EPIGENETICS MARKET FOR DNA POLYMERASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 124 NORTH AMERICA: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 EUROPE: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 126 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 127 LATIN AMERICA: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 128 MIDDLE EAST: EPIGENETICS MARKET FOR DNA POLYMERASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 129 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA POLYMERASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 EPIGENETICS MARKET FOR DNA LIGASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 131 NORTH AMERICA: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 EUROPE: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 133 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134 LATIN AMERICA: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 MIDDLE EAST: EPIGENETICS MARKET FOR DNA LIGASES, BY REGION, 2024–2031 (USD MILLION)
TABLE 136 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA LIGASES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY REGION, 2024–2031 (USD MILLION)
TABLE 138 NORTH AMERICA: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 139 EUROPE: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140 ASIA PACIFIC: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141 LATIN AMERICA: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142 MIDDLE EAST: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY REGION, 2024–2031 (USD MILLION)
TABLE 143 GCC COUNTRIES: EPIGENETICS MARKET FOR TN5 TRANSPOSASE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144 EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 145 NORTH AMERICA: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146 EUROPE: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 147 ASIA PACIFIC: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 LATIN AMERICA: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 149 MIDDLE EAST: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 150 GCC COUNTRIES: EPIGENETICS MARKET FOR CONVERSION ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 152 NORTH AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153 EUROPE: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 154 ASIA PACIFIC: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155 LATIN AMERICA: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156 MIDDLE EAST: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 157 GCC COUNTRIES: EPIGENETICS MARKET FOR PROTEIN-MODIFYING ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158 EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 159 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160 EUROPE: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 163 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER ENZYMES, BY REGION, 2024–2031 (USD MILLION)
TABLE 164 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER ENZYMES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165 EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 166 NORTH AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167 EUROPE: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168 ASIA PACIFIC: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 LATIN AMERICA: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 MIDDLE EAST: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 171 GCC COUNTRIES: EPIGENETICS MARKET FOR INSTRUMENTS & ACCESSORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 172 EPIGENETICS MARKET, BY SERVICE, 2024–2031 (USD MILLION)
TABLE 173 EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 174 NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 LATIN AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 178 MIDDLE EAST: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 179 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA METHYLATION PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 180 EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 181 NORTH AMERICA: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 EUROPE: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183 ASIA PACIFIC: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 184 LATIN AMERICA: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 185 MIDDLE EAST: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 186 GCC COUNTRIES: EPIGENETICS MARKET FOR CHROMATIN PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187 EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 188 NORTH AMERICA: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 EUROPE: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190 ASIA PACIFIC: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 191 LATIN AMERICA: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 192 MIDDLE EAST: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 193 GCC COUNTRIES: EPIGENETICS MARKET FOR CHROMATIN ACCESSIBILITY PROFILING SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 195 NORTH AMERICA: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196 EUROPE: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 197 ASIA PACIFIC: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 198 LATIN AMERICA: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199 MIDDLE EAST: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 200 GCC COUNTRIES: EPIGENETICS MARKET FOR SINGLE-CELL EPIGENOMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 202 NORTH AMERICA: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203 EUROPE: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204 ASIA PACIFIC: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205 LATIN AMERICA: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 MIDDLE EAST: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 207 GCC COUNTRIES: EPIGENETICS MARKET FOR MULTI-OMICS SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 208 EPIGENETICS MARKET FOR OTHER SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 209 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210 EUROPE: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER SERVICES, BY REGION, 2024–2031 (USD MILLION)
TABLE 214 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER SERVICES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 215 EPIGENETICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 216 EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024–2031 (USD MILLION)
TABLE 217 NORTH AMERICA: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218 EUROPE: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219 ASIA PACIFIC: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220 LATIN AMERICA: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 221 MIDDLE EAST: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024–2031 (USD MILLION)
TABLE 222 GCC COUNTRIES: EPIGENETICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 223 EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2024–2031 (USD MILLION)
TABLE 224 NORTH AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225 EUROPE: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226 ASIA PACIFIC: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 227 LATIN AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228 MIDDLE EAST: EPIGENETICS MARKET FOR PCR & QPCR, BY REGION, 2024–2031 (USD MILLION)
TABLE 229 GCC COUNTRIES: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230 EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 231 NORTH AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232 EUROPE: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 233 ASIA PACIFIC: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 234 LATIN AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 235 MIDDLE EAST: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 236 GCC COUNTRIES: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 237 EPIGENETICS MARKET FOR SONICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 238 NORTH AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 239 EUROPE: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240 ASIA PACIFIC: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 241 LATIN AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 242 MIDDLE EAST: EPIGENETICS MARKET FOR SONICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 243 GCC COUNTRIES: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 244 EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 245 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246 EUROPE: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 248 LATIN AMERICA: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 MIDDLE EAST: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 250 GCC COUNTRIES: EPIGENETICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 251 EPIGENETICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 252 EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 253 NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254 EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 256 LATIN AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 257 MIDDLE EAST: EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 258 GCC COUNTRIES: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 259 COMMON HISTONE MODIFICATIONS AND RESPECTIVE LOCATIONS
TABLE 260 EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 261 NORTH AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 262 EUROPE: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263 ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 264 LATIN AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 265 MIDDLE EAST: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 266 GCC COUNTRIES: EPIGENETICS MARKET FOR HISTONE MODIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 267 EPIGENETICS MARKET FOR OTHER METHODS, BY REGION, 2024–2031 (USD MILLION)
TABLE 268 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 269 EUROPE: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 270 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2024–2031 (USD MILLION)
LIST OF FIGURES
FIGURE 1 EPIGENETICS MARKET SEGMENTATION
FIGURE 2 EPIGENETICS MARKET: REGIONAL SCOPE
FIGURE 3 EPIGENETICS MARKET: YEARS CONSIDERED
FIGURE 4 MARKET SCENARIO
FIGURE 5 GLOBAL EPIGENETICS MARKET, 2024–2031
FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN EPIGENETICS MARKET, 2023–2026
FIGURE 7 DISRUPTIONS INFLUENCING GROWTH OF EPIGENETICS MARKET
FIGURE 8 HIGH-GROWTH SEGMENTS IN EPIGENETICS MARKET, 2026–2031
FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN EPIGENETICS MARKET DURING FORECAST PERIOD
FIGURE 10 GROWING EMPHASIS ON POPULATION SCREENING PROGRAMS TO DRIVE MARKET
FIGURE 11 DNA METHYLATION ACCOUNTED FOR LARGEST SHARE OF EPIGENETICS MARKET IN NORTH AMERICA IN 2025
FIGURE 12 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
FIGURE 13 PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 14 EPIGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 15 EPIGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 16 EPIGENETICS MARKET: VALUE CHAIN ANALYSIS
FIGURE 17 EPIGENETICS MARKET: ECOSYSTEM ANALYSIS
FIGURE 18 EPIGENETICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 19 INVESTMENT AND FUNDING SCENARIO, 2023–2026
FIGURE 20 PATENT APPLICATIONS IN EPIGENETICS MARKET, JANUARY 2015–DECEMBER 2025
FIGURE 21 IMPACT OF AI/GEN AI ON EPIGENETICS MARKET
FIGURE 22 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
FIGURE 23 KEY BUYING CRITERIA, BY END USER
FIGURE 24 EPIGENETICS MARKET, BY PRODUCT, 2024–2031 (MILLION UNITS)
FIGURE 25 NORTH AMERICA: EPIGENETICS MARKET SNAPSHOT
FIGURE 26 ASIA PACIFIC: EPIGENETICS MARKET SNAPSHOT
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN EPIGENETICS MARKET, 2021–2025
FIGURE 28 EPIGENETICS MARKET SHARE ANALYSIS, 2025
FIGURE 29 EPIGENETICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 30 EPIGENETICS MARKET: COMPANY FOOTPRINT
FIGURE 31 EPIGENETICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 33 EV/EBITDA OF KEY VENDORS
FIGURE 34 EPIGENETICS MARKET: BRAND COMPARATIVE ANALYSIS
FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 39 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 40 REVVITY: COMPANY SNAPSHOT (2025)
FIGURE 41 PACBIO: COMPANY SNAPSHOT (2025)
FIGURE 42 QIAGEN: COMPANY SNAPSHOT (2025)
FIGURE 43 HOLOGIC DIAGENODE: COMPANY SNAPSHOT (2025)
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025)
FIGURE 45 EPIGENETICS MARKET: RESEARCH DESIGN
FIGURE 46 EPIGENETICS MARKET: BREAKDOWN OF PRIMARIES
FIGURE 47 EPIGENETICS MARKET: INSIGHTS FROM PRIMARIES
FIGURE 48 GLOBAL EPIGENETICS MARKET ESTIMATION, 2025
FIGURE 49 EPIGENETICS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH), 2025
FIGURE 50 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE ANALYSIS (2025)
FIGURE 51 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 52 EPIGENETICS MARKET: CAGR PROJECTIONS
FIGURE 53 EPIGENETICS MARKET: DATA TRIANGULATION
FIGURE 1 EPIGENETICS MARKET SEGMENTATION
FIGURE 2 EPIGENETICS MARKET: REGIONAL SCOPE
FIGURE 3 EPIGENETICS MARKET: YEARS CONSIDERED
FIGURE 4 MARKET SCENARIO
FIGURE 5 GLOBAL EPIGENETICS MARKET, 2024–2031
FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN EPIGENETICS MARKET, 2023–2026
FIGURE 7 DISRUPTIONS INFLUENCING GROWTH OF EPIGENETICS MARKET
FIGURE 8 HIGH-GROWTH SEGMENTS IN EPIGENETICS MARKET, 2026–2031
FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN EPIGENETICS MARKET DURING FORECAST PERIOD
FIGURE 10 GROWING EMPHASIS ON POPULATION SCREENING PROGRAMS TO DRIVE MARKET
FIGURE 11 DNA METHYLATION ACCOUNTED FOR LARGEST SHARE OF EPIGENETICS MARKET IN NORTH AMERICA IN 2025
FIGURE 12 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
FIGURE 13 PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 14 EPIGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 15 EPIGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 16 EPIGENETICS MARKET: VALUE CHAIN ANALYSIS
FIGURE 17 EPIGENETICS MARKET: ECOSYSTEM ANALYSIS
FIGURE 18 EPIGENETICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 19 INVESTMENT AND FUNDING SCENARIO, 2023–2026
FIGURE 20 PATENT APPLICATIONS IN EPIGENETICS MARKET, JANUARY 2015–DECEMBER 2025
FIGURE 21 IMPACT OF AI/GEN AI ON EPIGENETICS MARKET
FIGURE 22 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
FIGURE 23 KEY BUYING CRITERIA, BY END USER
FIGURE 24 EPIGENETICS MARKET, BY PRODUCT, 2024–2031 (MILLION UNITS)
FIGURE 25 NORTH AMERICA: EPIGENETICS MARKET SNAPSHOT
FIGURE 26 ASIA PACIFIC: EPIGENETICS MARKET SNAPSHOT
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN EPIGENETICS MARKET, 2021–2025
FIGURE 28 EPIGENETICS MARKET SHARE ANALYSIS, 2025
FIGURE 29 EPIGENETICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 30 EPIGENETICS MARKET: COMPANY FOOTPRINT
FIGURE 31 EPIGENETICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 32 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 33 EV/EBITDA OF KEY VENDORS
FIGURE 34 EPIGENETICS MARKET: BRAND COMPARATIVE ANALYSIS
FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT (2025)
FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 39 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 40 REVVITY: COMPANY SNAPSHOT (2025)
FIGURE 41 PACBIO: COMPANY SNAPSHOT (2025)
FIGURE 42 QIAGEN: COMPANY SNAPSHOT (2025)
FIGURE 43 HOLOGIC DIAGENODE: COMPANY SNAPSHOT (2025)
FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025)
FIGURE 45 EPIGENETICS MARKET: RESEARCH DESIGN
FIGURE 46 EPIGENETICS MARKET: BREAKDOWN OF PRIMARIES
FIGURE 47 EPIGENETICS MARKET: INSIGHTS FROM PRIMARIES
FIGURE 48 GLOBAL EPIGENETICS MARKET ESTIMATION, 2025
FIGURE 49 EPIGENETICS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH), 2025
FIGURE 50 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE ANALYSIS (2025)
FIGURE 51 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 52 EPIGENETICS MARKET: CAGR PROJECTIONS
FIGURE 53 EPIGENETICS MARKET: DATA TRIANGULATION
